Although it is well known that the clinical expression and course of chronic inflammatory skin diseases are highly variable, there are insufficient epidemiological data on this, and the factors that determine the manifestation, clinical features and course are also largely unknown. There are currently no reliable markers that could predict or delineate patient subgroups to support patient management. The aim of this project is to identify clinical and molecular factors that correlate with disease, disease subtypes and progression through in-depth long-term clinical characterization of patients with chronic inflammatory skin diseases and examination of individual biomaterials.
dermatologist-diagnosed inflammatory skin disease
informed consent
subject and/or the legal guardians are not able to give written informed consent
pregnant and breastfeeding women
concurrent participation in a clinical trial
use of systemic immunosuppressive therapy or phototherapy during the last 4 weeks or receipt of biologics therapy (e.g. dupilumab, tralokinumab) within the last 3 months
Patients with chronic inflammatory skin disease Healthy control individuals
Cohort
Prospective
Topical and systemic drugs
DrugObservational study, treatment decisions are made independently as part of routine clinical care. Recruitment and follow-up will be independent on the type of treatment
Physician-assessed global disease activity
Change in Investigator Global Assessment (IGA, 0-5)
Patient-reported global disease activity
Change in Patient Global Assessment (IGA, 0-5)
Molecular features
Molecular and histopathological profiles in lesional skin and blood compared across diseases, over time and in response to therapy
Click on the lead sponsor to view all of their trials.
